Publications by authors named "Olumide Kayode"

Claim this Profile
N
NMR-Based Fragment Screen of the von Hippel-Lindau Elongin C&B Complex.
Kangsa Amporndanai, Jade M Katinas, Ashima Chopra, Olumide Kayode, Anish K Vadukoot

ACS Med Chem Lett· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
H, N, C backbone and Cβ resonance assignments for UBQLN1 UBA and UBAA domains.
Gwen R Buel, Xiang Chen, Olumide Kayode, Anthony Cruz, Kylie J Walters

Biomol NMR Assign· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
E6AP AZUL interaction with UBQLN1/2 in cells, condensates, and an AlphaFold-NMR integrated structure.
Gwen R Buel, Xiang Chen, Wazo Myint, Olumide Kayode, Varvara Folimonova

Structure· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer.
Ravi K Anchoori, Rosie Jiang, Shiwen Peng, Ruey-Shyang Soong, Aliyah Algethami, Olumide Kayode

ACS Omega· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of dacarbazine (DTIC) in pregnancy.
Ira Kantrowitz-Gordon, Karen Hays, Olumide Kayode, Aditya R Kumar, Henry G Kaplan

Cancer Chemother Pharmacol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors.
Andrea E Wahner Hendrickson, Michael E Menefee, Lynn C Hartmann, Harry J Long, Donald W Northfelt, Olumide Kayode

Clin Cancer Res· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small molecule inhibitors of mesotrypsin from a structure-based docking screen.
Olumide Kayode, Zunnan Huang, Alexei S Soares, Thomas R Caulfield, Zigang Dong

PLoS One· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Acrobatic Substrate Metamorphosis Reveals a Requirement for Substrate Conformational Dynamics in Trypsin Proteolysis.
Olumide Kayode, Ruiying Wang, Devon F Pendlebury, Itay Cohen, Rachel D Henin

J Biol Chem· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy.
Itay Cohen, Olumide Kayode, Alexandra Hockla, Banumathi Sankaran, Derek C Radisky

Biochem J· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mesotrypsin Has Evolved Four Unique Residues to Cleave Trypsin Inhibitors as Substrates.
Alexandre P Alloy, Olumide Kayode, Ruiying Wang, Alexandra Hockla, Alexei S Soares

J Biol Chem· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis